|
1
|
Elhourch S, Arrouchi H, Mekkaoui N, Allou Y, Ghrifi F, Allam L, Elhafidi N, Belyamani L, Ibrahimi A, Elomri N, Eljaoudi R. Significant Association of Polymorphisms in the TCF7L2 Gene with a Higher Risk of Type 2 Diabetes in a Moroccan Population. J Pers Med 2021; 11:jpm11060461. [PMID: 34073870 PMCID: PMC8225140 DOI: 10.3390/jpm11060461] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2021] [Revised: 05/20/2021] [Accepted: 05/21/2021] [Indexed: 12/06/2022] Open
Abstract
Background and aims: Several studies have shown that genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) are highly associated with the development of type 2 diabetes mellitus (T2DM) and its associated complications in several populations. The aim of our study was to investigate the association of the rs7903146 (C/T) and rs12255372 (G/T) polymorphism in the TCF7L2 gene with the risk of developing T2DM in the Moroccan population. Material and methods: A total of 150 T2DM patients and 100 healthy controls were recruited for various anthropometric, biochemical and genetic parameters. Genotyping was performed by using Real Time-PCR. The frequency of genotypes, alleles, anthropometric measures, glycemia, glycated hemoglobin (HbA1c) were evaluated in patients and control, while lipid profile was available only for T2DM group. Results: Glycemia, HbA1c and body mass index (BMI) were significantly higher in T2DM group than control. Analysis of the distribution of the TCF7L2 rs7903146 genotype and allele revealed that the TT genotype was more frequent in T2DM group (24.0%) than in healthy controls (5%) (OR = 4.08, 95% confidence interval (CI = 1.95–11.80, p < 0.0001). The T allele was more frequent in diabetic patients (45.2%) than healthy control (34.5%) and it was associated with high risk of diabetes (OR = 2.13, 95% CI = 1.12–7.31, p = 0.005). The same results were found regarding rs12255372, TT genotype frequencies were 18,7% and 6.0% in T2DM and control group, respectively (OR = 3.11, 95% CI = 1.33–7.24, p = 0.004). The T allele was over-presented in diabetics compared to controls (45.3% and 38.0%, respectively) and increases the risk of T2DM (OR = 2.01, 95% CI = 1.04–3.10, p = 0.01). However, there was no significant difference between the three genotypes of rs7903146 and rs12255372 regarding age, BMI, glycemia, HbA1c and lipid profile. Conclusion: The present study confirmed a significant association of the TCF7L2 gene (rs7903146 (C/T) and rs12255372 (G/T) polymorphisms with a higher risk to T2DM in the Moroccan population. No significant difference in respect to anthropometric and metabolic parameters between different genotypes.
Collapse
Affiliation(s)
- Sarah Elhourch
- Medical Biotechnology Laboratory (MedBiotech), Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed Vth University, 10000 Rabat, Morocco; (S.E.); (H.A.); (Y.A.); (F.G.); (L.A.); (N.E.); (A.I.)
| | - Housna Arrouchi
- Medical Biotechnology Laboratory (MedBiotech), Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed Vth University, 10000 Rabat, Morocco; (S.E.); (H.A.); (Y.A.); (F.G.); (L.A.); (N.E.); (A.I.)
| | - Nour Mekkaoui
- Clinical Research and Epidemiology Biostatistics Laboratory, Rabat Medical & Pharmacy School, Mohammed Vth University in Rabat, 10000 Rabat, Morocco;
| | - Younes Allou
- Medical Biotechnology Laboratory (MedBiotech), Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed Vth University, 10000 Rabat, Morocco; (S.E.); (H.A.); (Y.A.); (F.G.); (L.A.); (N.E.); (A.I.)
| | - Fatima Ghrifi
- Medical Biotechnology Laboratory (MedBiotech), Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed Vth University, 10000 Rabat, Morocco; (S.E.); (H.A.); (Y.A.); (F.G.); (L.A.); (N.E.); (A.I.)
| | - Loubna Allam
- Medical Biotechnology Laboratory (MedBiotech), Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed Vth University, 10000 Rabat, Morocco; (S.E.); (H.A.); (Y.A.); (F.G.); (L.A.); (N.E.); (A.I.)
| | - Naima Elhafidi
- Medical Biotechnology Laboratory (MedBiotech), Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed Vth University, 10000 Rabat, Morocco; (S.E.); (H.A.); (Y.A.); (F.G.); (L.A.); (N.E.); (A.I.)
- Immuno-Allergology Unit Children’s Hospital, 10000 Rabat, Morocco
| | - Lahcen Belyamani
- Military Hospital Mohammed V, Rabat Medical & Pharmacy School, Mohammed Vth University in Rabat, 10000 Rabat, Morocco; (L.B.); (N.E.)
| | - Azeddine Ibrahimi
- Medical Biotechnology Laboratory (MedBiotech), Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed Vth University, 10000 Rabat, Morocco; (S.E.); (H.A.); (Y.A.); (F.G.); (L.A.); (N.E.); (A.I.)
| | - Naoual Elomri
- Military Hospital Mohammed V, Rabat Medical & Pharmacy School, Mohammed Vth University in Rabat, 10000 Rabat, Morocco; (L.B.); (N.E.)
| | - Rachid Eljaoudi
- Medical Biotechnology Laboratory (MedBiotech), Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed Vth University, 10000 Rabat, Morocco; (S.E.); (H.A.); (Y.A.); (F.G.); (L.A.); (N.E.); (A.I.)
- Correspondence:
| |
Collapse
|